Article
Opportunity for pharmacogenomic testing in patients with cystic fibrosis.
Pediatric pulmonology - 1 Apr 2022
Sakon Colleen, Alicea Leah A, Patacca Heather, Brown Cynthia D, Skaar Todd C, Tillman Emma M
Abstract excerpt
BACKGROUND: Patients with cystic fibrosis (CF) are exposed to many drugs in their lifetime and many of these drugs have Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines that are available to guide dosing. Contemporary CF treatments are targeted to specific mutations in the CF transmembrane conductance regulator (CFTR) gene, and thus, require patients to have genetic testing before initiation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.